ReWalk Robotics (NASDAQ:LFWD – Get Free Report) had its price target decreased by analysts at Lake Street Capital from $6.00 to $4.50 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective would suggest a potential upside of 154.96% from the stock’s current price.
Several other equities analysts have also issued reports on the stock. Laidlaw assumed coverage on shares of ReWalk Robotics in a report on Monday, February 10th. They set a “buy” rating and a $10.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of ReWalk Robotics in a research note on Thursday.
Get Our Latest Analysis on ReWalk Robotics
ReWalk Robotics Price Performance
Insider Transactions at ReWalk Robotics
In other news, Director Michael Swinford acquired 21,622 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average cost of $2.03 per share, for a total transaction of $43,892.66. Following the acquisition, the director now directly owns 65,040 shares in the company, valued at approximately $132,031.20. The trade was a 49.80 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Global Fund Lp Lind II sold 381,676 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the transaction, the insider now directly owns 1,049,430 shares in the company, valued at $3,526,084.80. This trade represents a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.50% of the company’s stock.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Recommended Stories
- Five stocks we like better than ReWalk Robotics
- Dividend Capture Strategy: What You Need to Know
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- 3 REITs to Buy and Hold for the Long Term
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.